Full Text Journal Articles in
Journal Aliment Pharmacol Ther

Advertisement

Find full text journal articles






Prediction model for hepatocellular carcinoma occurrence in patients with hepatitis C in the era of direct-acting anti-virals.

Yuki Tahata, Ryotaro Sakamori, Ryoko Yamada, Takahiro Kodama, Hayato Hikita, Hideki Hagiwara, Yasuharu Imai, Naoki Hiramatsu, Shinji Tamura, Keiji Yamamoto, Masahide Oshita, Kazuyoshi Ohkawa, Taizo Hijioka, Hiroyuki Fukui, Toshifumi Ito, Yoshinori Doi, Yukinori Yamada, Takayuki Yakushijin, Yuichi Yoshida, Tomohide Tatsumi, Tetsuo Takehara, ,

<h4>Background</h4>Several factors associated with hepatocellular carcinoma (HCC) occurrence after sustained virological response (SVR) in patients with hepatitis C have been reported. However, few validation studies have been performed in the era of direct-acting anti-virals (DAAs).<h4>Aims</h4>To develop a prediction model for HCC occurrence after DAA-mediated SVR and validate its usefulness.<h4>Methods</h4>We analysed ... Read more >>

Aliment Pharmacol Ther (Alimentary pharmacology & therapeutics)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Agreement between local and central reading of endoscopic disease activity in ulcerative colitis: results from the tofacitinib OCTAVE trials.

Brian G Feagan, Reena Khanna, William J Sandborn, Séverine Vermeire, Walter Reinisch, Chinyu Su, Leonardo Salese, Haiyun Fan, Jerome Paulissen, Deborah A Woodworth, Wojciech Niezychowski, Bruce E Sands,

<h4>Background</h4>Endoscopy is routine in trials of ulcerative colitis therapies.<h4>Aim</h4>To investigate agreement between central and local Mayo endoscopic subscore (MES) reads in the OCTAVE programme METHODS: Flexible sigmoidoscopy was performed in tofacitinib induction (OCTAVE Induction 1&2, NCT01465763 and NCT01458951), maintenance (OCTAVE Sustain, NCT01458574) and open-label, long-term extension (OCTAVE Open, NCT01470612) studies. ... Read more >>

Aliment Pharmacol Ther (Alimentary pharmacology & therapeutics)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Advertisement

Editorial: the risk of chronic diseases and congenital malformations during childhood and adolescence after in utero drug exposure to thiopurines.

Robert N Lopez, Andrew S Day,

Aliment Pharmacol Ther (Alimentary pharmacology & therapeutics)
[2021, 54(8):1088-1089]

Cited: 0 times

View full text PDF listing >>



Letter: hepatocellular carcinoma risk in patients with non-selective beta blockers-authors' reply.

Karn Wijarnpreecha, Fang Li, Yifang Dang, C Burcin Taner, Liu Yang, Cui Tao,

Aliment Pharmacol Ther (Alimentary pharmacology & therapeutics)
[2021, 54(8):1095-1096]

Cited: 0 times

View full text PDF listing >>



Letter: universal screening for hepatitis C in pregnant women, children and adolescents.

Isabel Garrido, Guilherme Macedo,

Aliment Pharmacol Ther (Alimentary pharmacology & therapeutics)
[2021, 54(7):977-978]

Cited: 0 times

View full text PDF listing >>



Letter: universal screening for hepatitis C in pregnancy, children and adolescents-authors' reply.

Giuseppe Indolfi, Ersilia Lucenteforte,

Aliment Pharmacol Ther (Alimentary pharmacology & therapeutics)
[2021, 54(7):979-980]

Cited: 0 times

View full text PDF listing >>



Editorial: coeliac disease-it's a family affair. Authors' reply.

Saana Paavola, Katri Kaukinen, Kalle Kurppa,

Aliment Pharmacol Ther (Alimentary pharmacology & therapeutics)
[2021, 54(7):969]

Cited: 0 times

View full text PDF listing >>



Review article: the effectiveness of group and self-help hypnotherapy for irritable bowel syndrome and the implications for improving patients' choice and access to treatment.

Carolyn Gillan,

<h4>Background</h4>Individual hypnotherapy (IH) is a recognised treatment for irritable bowel syndrome (IBS). However, it is not widely available to patients due to its resource-intensive nature, lack of adequately trained therapists, and scepticism about hypnosis. Non-individualised hypnotherapy approaches, such as group and self-help hypnotherapy, could maximise existing therapist resources by treating ... Read more >>

Aliment Pharmacol Ther (Alimentary pharmacology & therapeutics)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Letter: hepatocellular carcinoma risk in patients with non-selective beta blockers.

Daniel Q Huang, Mindie H Nguyen,

Aliment Pharmacol Ther (Alimentary pharmacology & therapeutics)
[2021, 54(8):1093-1094]

Cited: 0 times

View full text PDF listing >>



Letter: is wireless oesophageal pH monitoring the best technique to evaluate night-time reflux? Authors' reply.

Jeroen M Schuitenmaker, Renske A B Oude Nijhuis, Albert J Bredenoord,

Aliment Pharmacol Ther (Alimentary pharmacology & therapeutics)
[2021, 54(7):976]

Cited: 0 times

View full text PDF listing >>



Editorial: time to retire Rome IV and the Montreal definition? Authors' reply.

Ming-Wun Wong, Chien-Lin Chen,

Aliment Pharmacol Ther (Alimentary pharmacology & therapeutics)
[2021, 54(8):1083-1084]

Cited: 0 times

View full text PDF listing >>



Letter: patients who have both sarcopenia and frailty have similar prognosis to those with either condition separately.

Theodoros Alexopoulos, Larisa Vasilieva, Meropi D Kontogianni, Iliana Mani, Alexandra Alexopoulou,

Aliment Pharmacol Ther (Alimentary pharmacology & therapeutics)
[2021, 54(7):981-982]

Cited: 0 times

View full text PDF listing >>



Letter: is wireless oesophageal pH monitoring the best technique to evaluate night-time reflux?

Mentore Ribolsi, Edoardo Savarino,

Aliment Pharmacol Ther (Alimentary pharmacology & therapeutics)
[2021, 54(7):974-975]

Cited: 0 times

View full text PDF listing >>



Bezafibrate therapy in primary biliary cholangitis refractory to ursodeoxycholic acid: a longitudinal study of paired liver biopsies at 5 years of follow up.

Juan Antonio Sorda, Esteban González Ballerga, Fernando Javier Barreyro, Alejandra Avagnina, Pilar Carballo, Andrea Paes de Lima, Jorge Daruich,

<h4>Background</h4>Ursodeoxycholic acid (UDCA) is the first-line therapy for primary biliary cholangitis (PBC). However, nearly 40% of patients have an incomplete response to UDCA. The addition of bezafibrate has shown biochemical benefit in this group of patients.<h4>Aim</h4>To evaluate the long-term effects of UDCA in combination with bezafibrate on histological outcomes in ... Read more >>

Aliment Pharmacol Ther (Alimentary pharmacology & therapeutics)
[2021, 54(9):1202-1212]

Cited: 0 times

View full text PDF listing >>



The impact of disease activity on psychological symptoms and quality of life in patients with inflammatory bowel disease-results from the Stress, Anxiety and Depression with Disease Activity (SADD) Study.

Thomas C Mules, Akhilesh Swaminathan, Esther Hirschfeld, Grace Borichevsky, Chris Frampton, Andrew S Day, Richard B Gearry,

<h4>Background</h4>Disease activity may be a risk factor for psychological illness in patients with inflammatory bowel disease (IBD).<h4>Aim</h4>To correlate objective measures of disease activity with psychological symptoms.<h4>Methods</h4>Adult patients with IBD undergoing ileocolonoscopy were prospectively recruited. Demographic, psychological symptoms (depression, anxiety, stress), disease activity (symptoms, biomarkers, endoscopy), and quality of life (QoL) ... Read more >>

Aliment Pharmacol Ther (Alimentary pharmacology & therapeutics)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Letter: the BSG COVID-19 interim coeliac disease guidance no-biopsy approach is safe in adults.

Lina Bourhan Tashtoush, Nicholas Charles Bosanko, Samuel Robin Broad, Ying Jenny Chan, Natasha Singhal, Sharon Saji, Nissy Saju, Anusha Shah, Ansab Zulfiqar, Melina Ilarionos, Siba Prosad Paul,

Aliment Pharmacol Ther (Alimentary pharmacology & therapeutics)
[2021, 54(8):1090-1092]

Cited: 0 times

View full text PDF listing >>



Editorial: time to retire Rome IV and the Montreal definition?

Peter J Kahrilas,

Aliment Pharmacol Ther (Alimentary pharmacology & therapeutics)
[2021, 54(8):1081-1082]

Cited: 0 times

View full text PDF listing >>



Editorial: coeliac disease-it's a family affair.

Amelie Therrien, Daniel A Leffler,

Aliment Pharmacol Ther (Alimentary pharmacology & therapeutics)
[2021, 54(7):967-968]

Cited: 0 times

View full text PDF listing >>



Editorial: higher concentrations of cytokine blockers are needed to obtain small bowel mucosal healing during maintenance therapy in Crohn's disease-authors' reply.

Kento Takenaka, Ami Kawamoto, Kazuo Ohtsuka,

Aliment Pharmacol Ther (Alimentary pharmacology & therapeutics)
[2021, 54(8):1087]

Cited: 0 times

View full text PDF listing >>



Editorial: higher concentrations of cytokine blockers are needed to obtain small bowel mucosal healing during maintenance therapy in Crohn's disease.

Shana Rakowsky, Adam S Cheifetz, Konstantinos Papamichael,

Aliment Pharmacol Ther (Alimentary pharmacology & therapeutics)
[2021, 54(8):1085-1086]

Cited: 0 times

View full text PDF listing >>



Review article: targeting the B cell activation system in autoimmune hepatitis.

Albert J Czaja,

<h4>Background</h4>The B cell activation system, consisting of B cell activating factor and a proliferation-inducing ligand, may have pathogenic effects in autoimmune hepatitis.<h4>Aims</h4>To describe the biological actions of the B cell activation system, indicate its possible role in autoimmune diseases, and evaluate its prospects as a therapeutic target in autoimmune hepatitis ... Read more >>

Aliment Pharmacol Ther (Alimentary pharmacology & therapeutics)
[2021, 54(7):902-922]

Cited: 0 times

View full text PDF listing >>



Letter: patients who have both sarcopenia and frailty have similar prognosis to those with either condition separately-authors' reply.

Chalermrat Bunchorntavakul, K Rajender Reddy,

Aliment Pharmacol Ther (Alimentary pharmacology & therapeutics)
[2021, 54(7):983-984]

Cited: 0 times

View full text PDF listing >>



Randomised clinical trial: dose optimising strategy by NUDT15 genotyping reduces leucopenia during thiopurine treatment of Crohn's disease.

Kang Chao, Yibiao Huang, Xia Zhu, Jian Tang, Xueding Wang, Lang Lin, Huili Guo, Caibin Zhang, Miao Li, Qingfan Yang, Jie Huang, Lingna Ye, Pinjin Hu, Min Huang, Qian Cao, Xiang Gao,

<h4>Introduction</h4>Thiopurine S-methyltransferase (TPTM) is a well known biomarker for thiopurine-induced leucopenia, which has limited value in Asia. Instead, NUDT15 C415T is a promising predictor in Asia.<h4>Aims</h4>To explore whether an optimised strategy based on NUDT15 C415T genotypes affects thiopurine-induced leucopenia, as well as efficacy in Chinese patients with Crohn's disease.<h4>Methods</h4>Patients with ... Read more >>

Aliment Pharmacol Ther (Alimentary pharmacology & therapeutics)
[2021, 54(9):1124-1133]

Cited: 0 times

View full text PDF listing >>



Lymphocytic gastritis and its relationships with other gastrointestinal disorders.

Robert M Genta, Anuradha Singhal, Kevin O Turner, Amnon Sonnenberg,

<h4>Background</h4>Lymphocytic gastritis (LyG) is a histopathologic finding of unknown clinical relevance.<h4>Aims</h4>To explore the clinical epidemiology of LyG and its associations with Helicobacter pylori (Hp) infection, coeliac disease (CD) and microscopic colitis (MC) METHODS: In a cross-sectional study, the demographic, clinical, and histopathologic data of patients with and without LyG were ... Read more >>

Aliment Pharmacol Ther (Alimentary pharmacology & therapeutics)
[2021, 54(9):1170-1178]

Cited: 0 times

View full text PDF listing >>



Population pharmacokinetics of subcutaneous infliximab CT-P13 in Crohn's disease and ulcerative colitis.

Jurij Hanzel, Laura H Bukkems, Krisztina B Gecse, Geert R D'Haens, Ron A A Mathôt,

<h4>Background</h4>Infliximab is a chimeric monoclonal antibody against tumour necrosis factor-alpha for the treatment of Crohn's disease (CD) and ulcerative colitis (UC). Recently, a subcutaneous formulation of CT-P13, an infliximab biosimilar, was approved for clinical use.<h4>Aims</h4>To characterise CT-P13 pharmacokinetics (PK) and its clinically relevant determinants after subcutaneous administration through population PK ... Read more >>

Aliment Pharmacol Ther (Alimentary pharmacology & therapeutics)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Advertisement


Disclaimer

1.2742 s